Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-641 +/- Pembrolizumab in Head and Neck Cancer
NCT04830592Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of NG-641 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Akamis Bio. Primary endpoint: Incidence of adverse events at Day 57. Started Nov 2021; status: completed.
02
Drugs
NG-641
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04830592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830592.